Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2021-10-13 Board/Management Inform…
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 99% confidence The document announces the appointment of a new Director of Research and Development (Dr. Thierry HUET) and states that this appointment 'finalise le renouvellement de notre équipe de management' (finalizes the renewal of our management team). This content directly relates to changes in senior management personnel. Therefore, the appropriate classification is Board/Management Information (MANG). The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-10-13 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new service, TeloSizer®, by the biotechnology company Genomic Vision. It details the product's features, market context (cellular health screening, telomere biology), and includes quotes from the CEO and Commercial Director. This type of announcement, focusing on a new product/service launch and its strategic implications, is characteristic of a general corporate update or press release. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR), and it is not explicitly about management changes (MANG), dividends (DIV), or capital structure (CAP), the most appropriate classification is a general Regulatory Filing (RNS) which serves as a broad category for official company announcements that don't fit elsewhere, or potentially an Earnings Release (ER) if this launch was tied to a specific reporting period, but the focus here is purely on a product launch, making RNS the better fit among the provided options for a general corporate news announcement.
2021-09-28 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Genomic Vision announcing the launch of a new service, TeloSizer®, related to telomere length measurement using their proprietary technology. It details the product, its market relevance (biomarkers, personalized medicine), and includes quotes from management. This type of announcement, focusing on a new product/service launch and its strategic implications, is characteristic of a general corporate update or press release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed interim report (IR). Since it is a specific corporate announcement about a new offering, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-standardized corporate communication, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate general category for a press release announcing a product launch that doesn't fit other specific financial/governance codes. Given the options, RNS serves as the best fit for a general corporate news announcement.
2021-09-28 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du Contrat de Liquidité" (Semi-annual balance sheet of the Liquidity Contract) and reports on the status of shares and cash held under a liquidity agreement as of June 30, 2021, covering the first semester of 2021. This is a periodic financial disclosure related to market operations, but it is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). It specifically details the activity under a liquidity contract, which is a form of capital/financing management disclosure. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it relates to the management of the company's stock liquidity mechanism, which is a financing/capital structure activity. It is too specific for a general Regulatory Filing (RNS) and does not fit the definitions of ER, IR, or AR.
2021-07-30 French
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport financier semestriel' (Interim Financial Report) for the period ending June 30, 2021. It contains comprehensive financial statements, management's discussion and analysis (Rapport semestriel d'activité), and an audit review report (Rapport du commissaire aux comptes). It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2021
2021-07-29 French
Inside Information / News release on accounts, results
Earnings Release Classification · 98% confidence The document explicitly announces the company's "FIRST-HALF 2021 RESULTS" and provides detailed financial tables (Revenue, Operating Loss, Net Loss) and commentary for the six months ended June 30, 2021. This content structure—a summary of financial performance for a period shorter than a full year—is characteristic of an Interim/Quarterly Report. Although it is presented as a press release, the core content is the comprehensive half-year financial disclosure, making 'Interim / Quarterly Report' (IR) the most appropriate classification over a simple 'Earnings Release' (ER) or 'Report Publication Announcement' (RPA), given its depth. The document also mentions the upcoming Q3 revenue publication, confirming its periodic reporting nature. H2 2021
2021-07-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.